This is the most important peptide comparison in the world right now.
Semaglutide started the category. Tirzepatide pulled ahead on weight loss outcomes. Retatrutide is the next-generation candidate everyone is watching.
The market conversation flattens all three into “GLP-1 drugs.” That framing is wrong in both directions — it makes early compounds sound more proven than they are, and it makes recent compounds sound less proven than they are. The three drugs are related, but they are not interchangeable, and the evidence backing them is not remotely equal.
Here’s what actually separates them.
1. Quick verdict
Semaglutide is the benchmark. The largest evidence base of any modern weight-loss drug, FDA-approved across multiple indications, and the default comparator for every newer entrant. Effective, well-characterized, widely available through prescription, and no longer cheap through any compounded channel.
Tirzepatide is the current leader on weight-loss outcomes. Dual agonist mechanism (GIP + GLP-1). Head-to-head data show greater average weight loss than semaglutide. Same general safety profile but slightly different side effect patterns. FDA-approved for type 2 diabetes and obesity. Access is prescription-gated and expensive, with compounding options largely wound down after the shortage resolution.
Retatrutide is a phase 3 candidate. Triple agonist (GLP-1 + GIP + glucagon). Phase 2 data showed the largest weight loss of any GLP-1-class compound tested to date — but the trial populations were small, phase 3 is still in progress, and long-term safety is still being characterized. Not approved. Any access to retatrutide today is happening outside regulated channels, and that changes the risk calculus significantly.
If you want the short version: semaglutide is proven and expensive. Tirzepatide is proven, slightly more effective, and slightly more expensive. Retatrutide is unproven in the sense that matters for clinical decision-making, even though the early signal is genuinely impressive.
2. Best fit by goal and context
This is where the market conversation usually breaks down. Each drug has a different profile, and the right choice depends heavily on what you’re actually trying to do.
For type 2 diabetes management: Semaglutide and tirzepatide both have strong indications and proven glycemic outcomes. Tirzepatide has shown somewhat stronger A1C reduction in head-to-head data, but both are first-line-tier treatments. Retatrutide is not approved for diabetes and should not be considered an option in this bucket.
For weight loss in obesity: Tirzepatide currently holds the weight-loss leadership among approved options. Semaglutide (as Wegovy) is still highly effective and has the longest track record. For most people in 2026, the decision here is between semaglutide and tirzepatide, based on availability, insurance coverage, and tolerability — not on chasing the biggest number.
For weight loss beyond what current approved drugs can deliver: Retatrutide’s phase 2 data showed larger average weight loss than either semaglutide or tirzepatide. This is the source of most of the retatrutide conversation. But “larger weight loss in a phase 2 trial” is not the same thing as “a drug you can responsibly take.” Phase 3 trials exist specifically to characterize safety, durability, and tolerability at scale. That work is still in progress.
For anyone risk-averse or evidence-first: Semaglutide. Period. It has the deepest, longest, most-replicated human evidence base of any drug in this class.
For anyone currently using a compounded GLP-1 and wondering what to do next: The compounded GLP-1 era has been contracting since late 2024. See the legality guide for the full context. The short version: if you’re on a compounded semaglutide or tirzepatide product today, the specific legal status of that product is not something you should assume from the seller’s marketing. It depends on the pharmacy type, the formulation, and the current state of ongoing enforcement and litigation.
3. Evidence comparison
This is the single most important dimension, and the place where the three drugs differ most.
Semaglutide. The evidence base is enormous. The SUSTAIN program established it for type 2 diabetes. The STEP program established it for obesity. The SELECT trial extended the evidence to cardiovascular outcomes in adults with obesity and existing cardiovascular disease, showing a meaningful reduction in major adverse cardiovascular events. There are supporting trials in kidney outcomes, heart failure with preserved ejection fraction, and ongoing work in other conditions. This is not “some evidence.” This is a drug with a mature, replicated, clinically decisive body of human data.
Tirzepatide. The evidence base is newer but already deep. The SURPASS program established it for type 2 diabetes, with head-to-head data showing superiority over semaglutide on glycemic and weight outcomes in the populations tested. The SURMOUNT program established it for obesity. Cardiovascular outcome trials are still running and are a major thing to watch. As of now, tirzepatide has a strong trial base, but less long-term follow-up data than semaglutide simply because it’s a younger drug.
Retatrutide. The evidence base is phase 2. That means: proof-of-concept trials in relatively small populations over relatively short durations. The phase 2 results were genuinely remarkable on weight loss. Phase 3 trials — the pivotal trials that determine approval — are ongoing. Long-term safety, durability of effect, tolerability at scale, cardiovascular outcomes, and real-world use are all still being studied. This is the normal progression of drug development. It is not a knock on the molecule. It is a statement about what the evidence does and does not currently support.
Where the market conversation gets this wrong: The common framing is “sema vs tirz vs reta, and reta wins.” That framing treats phase 2 headline numbers as equivalent to phase 3 approved outcomes. They are not. Phase 2 is where promising signals get validated or fail to replicate at scale. Most compounds that look exciting in phase 2 either get less exciting in phase 3, get more complicated on safety, or both. A non-trivial number don’t make it to approval at all. Retatrutide may sail through and become a category-defining drug. It may also hit unexpected issues. The honest current answer is: we don’t know yet, and that matters.
4. Safety comparison
All three drugs share a general side effect profile driven by their mechanism of action. Understanding that shared profile matters more than hunting for differences.
Shared side effects (all three):
- Gastrointestinal. Nausea, vomiting, diarrhea, constipation. These are the dominant side effects across the class, especially during dose escalation. They usually improve over time but are the main reason people discontinue treatment.
- Injection site reactions. Generally mild.
- Risk of hypoglycemia when combined with other glucose-lowering drugs (especially insulin or sulfonylureas).
- Gallbladder-related events. Rapid weight loss from any cause is associated with gallstone risk. GLP-1 drugs add to this because they slow gastric emptying.
- Pancreatitis signal. Historically flagged in class-level analysis, though the absolute risk in large trials has been low. Anyone with a history of pancreatitis needs to discuss it with a clinician.
- Thyroid C-cell tumor warning (class-wide, based on rodent studies). Approved labels carry this warning. The human signal is uncertain and contested.
Differences that actually matter:
- Tirzepatide may have slightly more pronounced GI side effects at equivalent efficacy, though individual tolerance varies widely.
- Semaglutide’s long track record means rarer side effects are better characterized. With tirzepatide, slightly longer follow-up is still accumulating.
- Retatrutide’s safety profile is not well characterized. Phase 2 data showed similar class-level side effects, but phase 2 populations are not large enough to reliably detect uncommon risks. The glucagon agonism adds a new pharmacological dimension whose long-term implications are still being studied.
Where the market conversation gets this wrong: “GLP-1 drugs are perfectly safe” and “GLP-1 drugs have hidden dangers” are both badly oversimplified. The real picture: for approved indications under clinician supervision, semaglutide and tirzepatide have well-characterized, manageable safety profiles for most patients. The main reason for discontinuation is GI tolerability, not serious adverse events. Retatrutide is in an earlier stage of characterization, which is a reason for caution — not panic.
5. Legal and access comparison
This is where the three drugs diverge dramatically.
Semaglutide.
- FDA-approved (Ozempic for T2D, Wegovy for obesity, Rybelsus as oral for T2D).
- Prescription-gated. Fully legal via prescription.
- Shortage resolved early 2025. Broad compounding no longer permitted under the shortage rule. Compounding continues in narrower 503A individual-patient contexts and in legally contested “personalized formulation” contexts.
- Insurance coverage is inconsistent. Obesity indication is covered by some plans but not others.
- Cash price through a regulated pharmacy remains substantial.
Tirzepatide.
- FDA-approved (Mounjaro for T2D, Zepbound for obesity).
- Prescription-gated. Fully legal via prescription.
- Shortage resolved late 2024. Same compounding contraction as semaglutide.
- Insurance coverage pattern similar to semaglutide — more consistent for T2D than for obesity.
- Cash price through a regulated pharmacy remains substantial, comparable to or slightly higher than semaglutide.
Retatrutide.
- Not approved for any indication. Phase 3 trials are ongoing.
- No legal prescription pathway exists outside of clinical trial participation.
- All other access is through “research use only” vendors — an unregulated supply chain with no quality guarantees, no clinician involvement, and no safety net. Both the compound identity and the purity of retatrutide sold through research-chemical vendors are unverifiable without third-party testing on your specific batch.
- The legal exposure of retatrutide sellers is significant. The legal exposure of purchasers is more uncertain and depends on jurisdiction, but buying and self-administering an unapproved drug is outside the regulated medical system in every way that matters.
See the full legality guide for the context on compounded medications, research-use-only labeling, and what the FDA is actually enforcing.
6. Cost and complexity comparison
Semaglutide and tirzepatide (regulated pharmacy path):
- Branded list prices run into the hundreds to thousand-plus dollars per month for full adult obesity doses.
- Insurance coverage varies heavily by plan, state, and indication.
- Copay assistance programs exist for both manufacturers but have limits and eligibility restrictions.
- Practical complexity is moderate: clinician visit, prescription, pharmacy pickup, titration schedule.
Semaglutide and tirzepatide (compounded path, where still available):
- Dramatically cheaper than the branded versions during the shortage era (often by 60–80 percent).
- Post-shortage, the pricing landscape is fragmented and legally contested.
- Quality varies by pharmacy. 503A compounding under individual prescription is a different animal from 503B bulk production, and both are different from telehealth platforms selling “personalized formulations.”
- Practical complexity depends on the operator. Trust in the vendor is the load-bearing variable.
Retatrutide (research-chemical path, the only non-trial path that exists today):
- Cash price through research-chemical vendors is a fraction of the compounded semaglutide price and a small fraction of branded prices.
- The cost of poor quality, incorrect identity, or contamination is not on the price tag.
- Practical complexity is significantly higher: self-sourcing, self-administration, reconstitution, dose calculation, cold-chain handling, and all of the verification work that a regulated pharmacy would normally do on your behalf.
- “Cheap” in one column is not “cheap” across all columns.
7. Hype gap comparison
The hype gap is how far public enthusiasm exceeds the quality of the underlying evidence.
Semaglutide: low hype gap. The drug genuinely does what it’s widely described as doing, backed by a mature human evidence base. Some specific claims (cardiovascular benefit, kidney benefit) are stronger than others (broader longevity benefits), but the core weight-loss and glycemic story is well-supported.
Tirzepatide: low hype gap. The head-to-head superiority on weight loss is real and replicated. The cardiovascular story is still being written — that’s a reason for measured confidence, not skepticism of the existing indications.
Retatrutide: high hype gap. This is the most important thing to understand about retatrutide specifically. The phase 2 weight loss numbers were remarkable. The online conversation has treated those numbers as if they are equivalent to phase 3 outcomes or approved-drug outcomes. They are not. The gap between “phase 2 headline number” and “drug you can responsibly rely on” is precisely what phase 3 trials exist to measure. Retatrutide may end up fully validating the early signal. It may also get more complicated on safety, tolerability, or durability. Treating a phase 2 trial as a finish line is the core hype-gap move in this space.
This pattern — phase 2 excitement interpreted as phase 3 certainty — shows up repeatedly in peptide content. It’s one of the main reasons the category’s market conversation is unreliable.
8. Bottom line
Semaglutide is the benchmark. If you want the drug with the deepest human evidence and the longest safety track record, it’s semaglutide.
Tirzepatide is the current leader for approved weight-loss outcomes. If you have access to it via a regulated pharmacy and a prescription, and the tradeoffs work for you, it’s a defensible choice.
Retatrutide is the most promising next step in the class — and the one where the evidence most clearly does not yet support the level of enthusiasm surrounding it. If you’re in a phase 3 clinical trial, that’s a real pathway. If you’re not, the “access” you’re hearing about is research-chemical commerce with no clinical safety net, using a drug whose long-term human profile is still being written.
The honest summary: in 2026, the approved drugs are still the approved drugs, and the unapproved ones are still unapproved, no matter how exciting the early signal looks.
If you’re trying to make a decision about any of the three, do three things: read the actual trial data (not the summaries), talk to a clinician who isn’t selling you anything, and check the current regulatory status of the specific pathway you’re considering before you commit to it.
9. The Peptide Addict Scorecards
Where to go next
- The Beginner’s Guide to Peptides — the foundational reference on what peptides are and why they’re everywhere.
- Are Peptides Legal in 2026? — the plain-English guide to approved, compounded, and research-use-only pathways.
- BPC-157: What Human Evidence Actually Exists? — the case study in how hype outruns human data.
- How to Evaluate a Peptide Vendor — if you’re considering a research-chemical or compounded purchase, this is the methodology to use.
Nothing in this article is medical advice. The Peptide Addict is an editorial publication. Consult a licensed clinician before making any decision about compounds, drugs, or medical treatment.